gliclazide
Small moleculeexperimental
Gliclazide, sold under the brand name Diamicron among others, is a sulfonylurea type of anti-diabetic medication, used to treat type 2 diabetes. It is used when dietary changes, exercise, and weight loss are not enough. It is taken by mouth. — Wikipedia
Clinical trial activity
50 trials · 61 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
9
Phase 3
8
Phase 4
25
Earliest trial started Jun 1, 2001 (NCT00145925)
Timeline
Indications
Approved for
Studied for
- Angina Pectoris · Phase 4
- Bone Diseases, Metabolic · Phase 4
- Diabetes Mellitus, Type 2 · Phase 4
- Diabetic Nephropathies · Phase 4
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Endothelium · Phase 3
- Epilepsy · Phase 1
- Healthy Volunteers · Phase 1
- Menopause · Phase 4
- Non-alcoholic Fatty Liver Disease · Phase 4
- Osteoporosis · Phase 4
- Pharmacology · Phase 1
- Psoriasis · Phase 2
Mechanism of action
- Sulfonylurea receptor 1AGONIST
ABCC8 agonist
Sulfonylurea receptor 1, Kir6.2 blocker
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(S(=O)(=O)NC(=O)NN2CC3CCCC3C2)cc1- Mol. weight
- 323.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGliclazide ↗
- ChEMBLCHEMBL427216 ↗
Also known as
- 1-(3-azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea
- 1-(3-azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea
- 1-(hexahydrocyclopenta(c)pyrrol-2(1h)-yl)-3-(p-tolylsulfonyl)urea
- 1-(hexahydrocyclopenta(c)pyrrol-2(1h)-yl)-3-(p-tolylsulfonyl)urea
- bilxona
- dacadis mr
- diabezidum
- diabrezide
- diabyl
- diaglyk
- diaglyk
- diamicron
- diamicron
- diamicron
- diamicron mr
- diamicron mr
- diaprel
- dizalid
- edicil
- glicazide
- gliclazid
- gliclazida
- gliclazida
- gliclazide
- gliclazide
- gliclazide
- gliclazide
- gliclazide
- gliclazide
- gliclazide
- gliclazide
- gliclazide
- gliclazidum
- gliclazidum
- glimicron
- glimil
- glinormax
- glyzide
- n-(4-methylbenzenesulfonyl)-n'-(3-azabicyclo(3.3.0)oct-3-yl)urea
- n-(4-methylbenzenesulfonyl)-n'-(3-azabicyclo(3.3.0)oct-3-yl)urea
- nazdol mr
- s 1702
- se-1702
- se-1702
- vamju
- vitile xl
- ziclaseg
- zicron
- zicron pr
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06613750 | Phase 4 | Jun 1, 2024 | Guangzhou Medical University, Southern Medical University |
| NCT06222476 | N/A | Feb 20, 2024 | Nanjing University |
| NCT06085703 | N/A | Sep 1, 2023 | Nanjing University |
| NCT04198948 | Phase 1 | Mar 4, 2019 | University of Dundee, University of Sarajevo, Wilhelminenspital der Stadt Wien |
| NCT03819790 | Phase 4 | Oct 2, 2018 | LMC Diabetes & Endocrinology Ltd. |
| NCT03705195 | N/A | Aug 3, 2018 | University of Dundee |
| NCT03467971 | Phase 1 | Mar 6, 2018 | Merck KGaA |
| NCT03467945 | Phase 1 | Feb 16, 2018 | Merck KGaA |
| NCT03433248 | Phase 4 | Nov 9, 2017 | Free University of Amsterdam |
| NCT03313661 | Phase 3 | Oct 14, 2017 | Delta University for Science and Technology, Tanta University |
| NCT03804411 | Phase 4 | Aug 1, 2017 | Government of Russia |
| NCT03246828 | N/A | Jul 3, 2017 | University of Oxford |
| NCT02879409 | N/A | Nov 1, 2016 | Cornell University, Hamad Medical Corporation, Sidra Medical and Research Center, University of Hull |
| NCT02925559 | Phase 4 | Oct 1, 2016 | AstraZeneca, Centro de Diabetes Curitiba |
| NCT03164187 | Phase 4 | Sep 1, 2016 | Servier |
| NCT02694263 | Phase 4 | Jul 1, 2016 | University of Birmingham, University of Leicester |
| NCT02682563 | Phase 4 | Feb 1, 2016 | AstraZeneca, Free University of Amsterdam |
| NCT02643329 | Phase 1 | Jan 1, 2016 | Bright Future Pharmaceuticals Factory, Chinese University of Hong Kong |
| NCT02610088 | Phase 4 | Nov 1, 2015 | Seoul National University |
| NCT02201602 | Phase 4 | Aug 1, 2014 | Khoo Teck Puat Hospital |
Showing 20 of 50 trials
Page 1 / 3
Organizations
Research & Development (61)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Dundee | Academic/Hospital | 4 | 3 | 3 | 2007 |
| Merck | For profit | 3 | 3 | 2 | 2010 |
| Nanjing University | Academic/Hospital | 3 | 3 | 2 | 2014 |
| Novartis | For profit | 3 | 3 | 2 | 2005 |
| Novo Nordisk | For profit | 3 | 2 | 2 | 2002 |
| Servier | For profit | 3 | 2 | 2 | 2001 |
| AstraZeneca | For profit | 2 | 0 | 1 | 2016 |
| Centro de Diabetes Curitiba | Academic/Hospital | 2 | 2 | 1 | 2012 |
| Chinese University of Hong Kong | Academic/Hospital | 2 | 1 | 2 | 2011 |
| Free University of Amsterdam | Academic/Hospital | 2 | 2 | 1 | 2016 |
| GlaxoSmithKline | For profit | 2 | 1 | 1 | 2004 |
| Merck KGaA | For profit | 2 | 2 | 1 | 2018 |
| Sanofi | For profit | 2 | 2 | 2 | 2006 |
| Bial | For profit | 1 | 1 | 1 | 2007 |
| Bright Future Pharmaceuticals Factory | For profit | 1 | 1 | 1 | 2016 |
| Charles University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Delta University for Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Disphar International B.V. | For profit | 1 | 1 | 1 | 2014 |
| Government of China | Government | 1 | 0 | 1 | 2004 |
61 organizations
Page 1 / 4